Latest / Pharmacy Podcast Network / Custom Care for Kids: Pharmacogenomics in Pediatrics | Pediatric Pharmacist Review
Transcript
- 0:06Speaker 1: You are listening to the Pharmacy Podcast Network.
- 0:21Speaker 2: Adverse drug reactions, or ADRs, are a serious issue in
- 0:25Speaker 2: healthcare today. The pharmacist is the last line of defense
- 0:28Speaker 2: to help prevent ADRs. A rising role of the pharmacist
- 0:32Speaker 2: is the specialist who focuses on our children. Pediatric pharmacy
- 0:36Speaker 2: ensures safe and effective drug use and optimal medication therapy
- 0:40Speaker 2: outcomes and children up to eighteen years of age. Currently,
- 0:43Speaker 2: there are more than one four and fifty board certified
- 0:47Speaker 2: pediatric pharmacy specialists known as bps. If you're interested in
- 0:51Speaker 2: this expanding field of pharmacy, this podcast is for you.
- 0:55Speaker 2: All right, everyone, let's give it up for our host.
- 0:59Speaker 3: Hey, listeners, welcome back to the Pediatric Pharmacist Review. My
- 1:03Speaker 3: name is Justin Cole. I'm one of your hosts. I'm
- 1:06Speaker 3: here joined by Mary Voong. Mary, how have you been, jangl?
- 1:10Speaker 4: How are you justin?
- 1:11Speaker 5: Yeah?
- 1:12Speaker 4: Out of the blue screen of death?
- 1:14Speaker 3: Oh man. So many of you probably are very familiar
- 1:18Speaker 3: with that and have technology issues. Today has been my
- 1:20Speaker 3: day for those, so thankfully we're beyond them, and I
- 1:23Speaker 3: am excited to talk with our guests today. And our
- 1:27Speaker 3: guest is Kelly Caddle. Kelly is an expert in pharmacogenomics.
- 1:30Speaker 3: She's been really one of the I don't think this
- 1:33Speaker 3: is an overstatement worldwide leaders in helping to advance pharmacogenomics
- 1:38Speaker 3: and pediatric pharmacy practice, particularly with her post at Saint Jude's.
- 1:42Speaker 3: So we are really excited to talk about pharmaco genomics.
- 1:45Speaker 3: It's potential and even some of the pitfalls in for
- 1:47Speaker 3: in pediatric pharmacy practice today. So, Kelly, thank you so
- 1:50Speaker 3: much for joining us.
- 1:52Speaker 6: Oh no, hi, it's great to be here. I'm excited.
- 1:56Speaker 5: All right.
- 1:56Speaker 3: Well, we know that precision medicine play is an elay
- 2:00Speaker 3: important role in today's practice. We've had a lot of initiatives,
- 2:06Speaker 3: even for at the federal government level, kind of pushing
- 2:09Speaker 3: us towards that, and of course precision medicine is a
- 2:11Speaker 3: really broad term, right. Only one little piece of that though,
- 2:16Speaker 3: is figuring out what pharmacogenetic data we have available and
- 2:20Speaker 3: how we can use that to reduce those unwanted side
- 2:23Speaker 3: effects in target therapy. So, Kelly, I just wanted to
- 2:26Speaker 3: open this up and let you tell our listeners a
- 2:30Speaker 3: little bit about your role and maybe you can define
- 2:32Speaker 3: for us what pharmacogenetics.
- 2:35Speaker 6: Is Okay, no, no problem.
- 2:36Speaker 5: So I'll start with the second question, what is pharmacogenemics.
- 2:40Speaker 6: So pharmacogenemics is.
- 2:42Speaker 5: Really just how variations in your genetic code can impact
- 2:45Speaker 5: how you respond to drugs, either it be a toxicity
- 2:48Speaker 5: or efficacy of that particular drug.
- 2:51Speaker 6: My role over the last twelve years, I've.
- 2:53Speaker 5: Been at Saint Jude, and we knew back in twenty
- 2:57Speaker 5: twelve that we had lots of days on pharmacogenomics and
- 3:01Speaker 5: how and somewhat how to use it in patients, but
- 3:04Speaker 5: nobody really truly understood how to take this data and change,
- 3:08Speaker 5: you know, practice with it. And so I worked back
- 3:11Speaker 5: with Mary Rewlling back in twenty twelve, and actually she's
- 3:14Speaker 5: the one that started it really in twenty ten, but
- 3:16Speaker 5: I joined the team in twenty twelve and she started CPICK,
- 3:19Speaker 5: the Clinical Pharmacogenetics Implementation Consortium. We have been a shared
- 3:23Speaker 5: project between Saint Jude and our COPI at Stanford Terry Klein.
- 3:29Speaker 6: Since this time. We've been NIH funded, but.
- 3:31Speaker 5: Our main goal is to write clinical practice guidelines for
- 3:35Speaker 5: really how do you take just that raw genetic data
- 3:38Speaker 5: and interpret it all the way up to how you
- 3:41Speaker 5: would use it in a patient. So either that be
- 3:43Speaker 5: you know, change of a drug or change of a dose.
- 3:47Speaker 5: So it's really just taken the knowledge that we have.
- 3:49Speaker 6: And trying to applying it to patient care.
- 3:52Speaker 4: With the knowledge that we have.
- 3:53Speaker 7: I know that for a lot of people, pharmac would
- 3:55Speaker 7: you know, makes is something that's like pretty new. I
- 3:57Speaker 7: was actually fortunate enough to have an elective in so
- 4:00Speaker 7: I did like a full semester on it, and my
- 4:02Speaker 7: hospital did try to implement like a huge farm gua
- 4:05Speaker 7: genomics program. But for our listeners out there who didn't
- 4:08Speaker 7: have these luxuries, what are specific gene variants that you
- 4:11Speaker 7: would say are like the red flags that like, if
- 4:13Speaker 7: someone sees it, we should definitely look further.
- 4:17Speaker 5: Oh, I know there's a lot in my opinion, but
- 4:19Speaker 5: I think, you know, for for pediatric oncology specifically, I
- 4:21Speaker 5: think we we think a lot about the use of
- 4:25Speaker 5: you know, thiopurines, especially when we're treating all and I
- 4:28Speaker 5: think the big ones they are TPMT and ninety fifteen.
- 4:31Speaker 6: These are two genes that can impact thioppearing toxicity.
- 4:36Speaker 5: And it really with patients who are what we consider
- 4:39Speaker 5: a poor metabolizer for TPMT and.
- 4:42Speaker 6: Or you can be both for both of these genes.
- 4:45Speaker 5: Most patients are only for one and it's actually fairly rare,
- 4:49Speaker 5: but these patients have a greatly increased risk with thiopurin
- 4:52Speaker 5: related lucipenia, neutropenia, and mylosuppression. And this has become really
- 4:57Speaker 5: important in our in our kind of our smaller world.
- 5:00Speaker 6: That we have in pediatric oncology.
- 5:01Speaker 5: These are actually been now that testing for NUTT fifteen
- 5:04Speaker 5: and TPMT are now recommended in some of the clinical
- 5:08Speaker 5: practice guidelines, such as the CG protocols in cc IN guidelines,
- 5:12Speaker 5: and they actually do cite c PICK directly and use
- 5:15Speaker 5: our recommendations.
- 5:16Speaker 6: That are that are in our guidelines.
- 5:18Speaker 5: There's also a lot for supportive care that I think
- 5:21Speaker 5: are really important, but from a toxicity standpoint, I really
- 5:25Speaker 5: think that that TPMT ninety fifteen are probably the most
- 5:28Speaker 5: And then there's on you know, on the other flip side,
- 5:30Speaker 5: you know, outside of the peds we have colon cancer,
- 5:32Speaker 5: and there's DPYD and the use in floor premedines, which
- 5:36Speaker 5: is another big one where if you know that your
- 5:38Speaker 5: patient support metabolizer, you could you could do a lot
- 5:41Speaker 5: of harm giving them a full dose of these drugs
- 5:43Speaker 5: and there're actually been lawsuits against that one for a
- 5:46Speaker 5: physician ignoring some of these results. So from a toxicity standpoint,
- 5:50Speaker 5: I think it's more related to the cancer meds because
- 5:52Speaker 5: they're just very toxic, but a lot of genetic variations
- 5:56Speaker 5: for some things like on dantatron anti depressants. You know,
- 5:59Speaker 5: trying to find that right dose for your patient is
- 6:02Speaker 5: very and right drug is very difficult, and so having
- 6:05Speaker 5: something like pharmacogenemics to at least guide that first selection
- 6:09Speaker 5: and drug I think can be really helpful, especially in pediatrics.
- 6:13Speaker 5: And then of course that the use of opioids, and
- 6:16Speaker 5: there's a lot of information out there about two D
- 6:18Speaker 5: six and adverse reactions for coding and these did happen
- 6:24Speaker 5: in children as well, so lots there's a lot.
- 6:27Speaker 6: So you can go to the seat Pick website you'll
- 6:28Speaker 6: see there's lots.
- 6:29Speaker 5: Of variations that we think are important, But I do
- 6:31Speaker 5: I still think the ones that affect our cancer me
- 6:33Speaker 5: as are probably at the top of that list.
- 6:37Speaker 3: Yeah, Kelly, as a Seapick member myself, and I'll admit
- 6:40Speaker 3: I don't have the level of expertise that you do
- 6:42Speaker 3: in this at all, but I try to attend to
- 6:44Speaker 3: all the meetings, and what I love most about sea
- 6:46Speaker 3: Pick just putting the quick plug in there, is that
- 6:49Speaker 3: you have a group of experts who are really dedicated
- 6:53Speaker 3: to translating this knowledge to the bedside right making it
- 6:56Speaker 3: super practical and actionable for clin It's heavily evidence based,
- 7:02Speaker 3: so these aren't These aren't just experts sitting in a
- 7:05Speaker 3: room deciding what they think should be done. They're actually
- 7:08Speaker 3: evaluating critically the evidence and making great tools that are available.
- 7:12Speaker 3: We'll probably talk about some of those later, like farm
- 7:14Speaker 3: GKB and then some others too, but I'm just always
- 7:19Speaker 3: impressed with the work that Cepick does to help us
- 7:21Speaker 3: to be able to implement these beyond just prpd's patients,
- 7:24Speaker 3: but also in adults. So Kelly, you really quickly. They're
- 7:30Speaker 3: touched on SIP two D six and opioids, and a
- 7:34Speaker 3: lot of our listeners are in general pediatrics and other places,
- 7:37Speaker 3: so I think SIP twoty six is just a great
- 7:41Speaker 3: case to talk about for everyone. So could you maybe
- 7:44Speaker 3: talk about the importance of SIP two D six and
- 7:47Speaker 3: opioids in particular. Again, they apply to pediatric oncology as
- 7:51Speaker 3: well as you said.
- 7:53Speaker 6: Oh right, So SIP two D six, so coding, especially
- 7:55Speaker 6: coding and tim it all.
- 7:57Speaker 5: There are some there's some evidence for high your codone,
- 8:00Speaker 5: but it's not quite as as strong and it is
- 8:03Speaker 5: for codeine and tramadol. As you may know, coding and
- 8:06Speaker 5: tramidol are both pro drugs, so really without being metabolized
- 8:10Speaker 5: by SIP two D six to an active drug, these
- 8:13Speaker 5: drugs really don't work.
- 8:14Speaker 6: So the poor and this is kind of reverse in
- 8:16Speaker 6: what you usually.
- 8:17Speaker 5: Think about it because it's a because because it's a
- 8:19Speaker 5: pro drug, but in a poor metabolizer, these patients really
- 8:22Speaker 5: are not making any any of the active medication, So
- 8:24Speaker 5: these drugs may not work on these individuals. And hydrocode
- 8:28Speaker 5: one falls in that as well, but hydro codon does
- 8:29Speaker 5: have some activity in the parent drug, so these patients
- 8:33Speaker 5: may have some efficacy of the drug. But what is
- 8:36Speaker 5: kind of scary is on the flip side of this,
- 8:38Speaker 5: if you're a SIP two D six what we call
- 8:40Speaker 5: an ultra rapid metabolizer, so you're just metabolizing very quickly,
- 8:44Speaker 5: so you're getting a lot more of the constant concentration
- 8:47Speaker 5: of that active metabolite, and these patients you can have
- 8:52Speaker 5: major toxicities to these drugs, and there have been several
- 8:54Speaker 5: case reports of these toxicities. You know, maybe the most
- 8:58Speaker 5: famous one, of course is the breast eating mother taking codeine.
- 9:01Speaker 5: She was an ultra apid metabolizer and the infant unfortunately
- 9:04Speaker 5: got too much morphine in that in that in that situation.
- 9:08Speaker 5: And so that's actually where we kind of started to
- 9:10Speaker 5: discovered that this was a really important pharmacogene for for opioids.
- 9:13Speaker 6: But but you know SIP.
- 9:14Speaker 5: Two D six, after you know the in the and
- 9:16Speaker 5: I'd like to bring this up a little bit here,
- 9:18Speaker 5: but once you've tested for SIP two D six, you've
- 9:20Speaker 5: got it in your your the patient's got that information.
- 9:22Speaker 6: There are a lot of drugs that are impacted by
- 9:24Speaker 6: SIP two D six. So even though we may.
- 9:27Speaker 5: Have ordered that test for the opioids, you have to
- 9:30Speaker 5: think that it also can affect that antidepressants and on dantaitron.
- 9:33Speaker 5: I think I said that in a few more, few
- 9:34Speaker 5: more drugs out there as well, because SIP two D
- 9:37Speaker 5: six metabolizes a lot of drugs. So I think there's
- 9:40Speaker 5: still a lot to be undiscovered with SIP two D six.
- 9:43Speaker 5: It's a bit of a messy drug. I mean messy
- 9:45Speaker 5: gene in some ways. There's a lot of variation in
- 9:48Speaker 5: this drug, so studying it can be very difficult as well.
- 9:51Speaker 6: So yeah, I think hopefully that answered your question.
- 9:55Speaker 3: Yeah, absolutely, And and you're right SIP two D six
- 9:58Speaker 3: and and of course the number of the other pharmacogenes
- 10:00Speaker 3: that we're looking at have impacts across multiple disease states.
- 10:05Speaker 3: Once we have this data, it stays with us, right,
- 10:08Speaker 3: And so that brings me to a quick question that
- 10:11Speaker 3: I wanted to ask you, which is more about maybe
- 10:15Speaker 3: the implementation and documentation of this information in our electronic
- 10:19Speaker 3: health records and things like that. Do you have any
- 10:22Speaker 3: suggestions on best practices to make this information transferable to
- 10:27Speaker 3: providers and easily seen. One of the biggest concerns that
- 10:31Speaker 3: I've had when it comes to implementing pharmacogenemics and the
- 10:34Speaker 3: systems I've worked in is that they're not meant to
- 10:39Speaker 3: a how's the information discreetly? And then number two to
- 10:43Speaker 3: be able to make any clinical decision support off of that. Right.
- 10:48Speaker 3: So I know we're kind of getting more into the
- 10:50Speaker 3: administrative side of how do you take this to care?
- 10:53Speaker 3: But I'd love to just hear from your expertise at
- 10:56Speaker 3: Saint Jude and some of the things that you've done.
- 10:58Speaker 3: How do you make this data documentable and actionable such
- 11:02Speaker 3: that if there is a child receiving a different medication
- 11:05Speaker 3: other than a chemotherapy agent or something for supportive care,
- 11:08Speaker 3: we can actually see and put possibly use that data.
- 11:12Speaker 5: So we're very lucky at Saint Jude and that they've
- 11:15Speaker 5: really embraced pharmaca jemics pretty early on. So for about
- 11:18Speaker 5: ten years we've had a program where we preemptively test
- 11:21Speaker 5: our patients. And I mean we're in the not maybe
- 11:24Speaker 5: nine thousand patients now, and I don't really know that
- 11:26Speaker 5: full number, but we've tested thousands of patients, so they
- 11:31Speaker 5: pretty much get approached about our protocol the second they
- 11:34Speaker 5: walk through the door here at Saint Jude, and so
- 11:36Speaker 5: we test I think we're up to thirteen genes now.
- 11:38Speaker 5: So you can imagine that we really had to have
- 11:40Speaker 5: a place to store these. I mean, as you're right,
- 11:42Speaker 5: it's not like a glucose where you want to order
- 11:44Speaker 5: that every day and it's got this time stamp on it.
- 11:46Speaker 5: This result will really follow the patient throughout their life,
- 11:49Speaker 5: and there's some caveats to that.
- 11:51Speaker 6: You know, we got to really think about what variants
- 11:53Speaker 6: were tested.
- 11:53Speaker 5: But for the most part, unless they're retested sometime down
- 11:56Speaker 5: the line, this is their test result and so it
- 11:59Speaker 5: becomes really tricky once they.
- 12:00Speaker 6: Leave the hospital. But once and I'll talk about that
- 12:03Speaker 6: in a second.
- 12:03Speaker 5: But once they're here in the hospital, these do go
- 12:06Speaker 5: into our medical record.
- 12:08Speaker 6: We went from Startner to EPIC very recently, so that
- 12:10Speaker 6: was fun.
- 12:10Speaker 5: So we build all this in Cerner and then had
- 12:13Speaker 5: to go and I'll give Serene hay To our credit
- 12:15Speaker 5: for those, because you're the one that runs our program
- 12:17Speaker 5: at Saint Jude and she's done a phenomenal job, but
- 12:19Speaker 5: pretty much had to reproduce everything that we had done
- 12:21Speaker 5: in Cerner into EPIC.
- 12:23Speaker 6: But it's still kind of the same. It still runs the.
- 12:25Speaker 5: Same way where we put the test result and we
- 12:27Speaker 5: use the phenotype mostly so if we know they're a
- 12:29Speaker 5: SIP two D six for metabolizer.
- 12:31Speaker 6: There are snowmed terms for this.
- 12:33Speaker 5: This was actually created by CPICK that was standardization project,
- 12:37Speaker 5: so that it's there, it's easily grappable. You can make
- 12:39Speaker 5: it a way that you can discreetly put this into
- 12:42Speaker 5: the medical record.
- 12:44Speaker 6: Some people put it in as an allergy.
- 12:46Speaker 5: Sometimes you see it in there as an on the
- 12:48Speaker 5: problem list.
- 12:50Speaker 6: We actually created an.
- 12:51Speaker 5: Entire folder for pharmacogenemics because we're testing so many genes
- 12:53Speaker 5: and we didn't want to clog up a problem list.
- 12:56Speaker 5: But because they're indiscreetly, if a physician goes in there
- 12:58Speaker 5: and orders a drug U they get a and the
- 13:01Speaker 5: patient has what we consider a high risk result, so
- 13:03Speaker 5: they're that SIP two D six poor metabolizer and the
- 13:06Speaker 5: physician has ordered coding, patient's older than twelve, has ordered coding,
- 13:11Speaker 5: and they'll get this alert that says, hey, your patient's
- 13:14Speaker 5: a SIP two D six por metabolizer, and it has
- 13:16Speaker 5: the seed pick recommendation right there at the point of
- 13:19Speaker 5: care for that physician or the prescriber to look at.
- 13:22Speaker 5: And we've been really lucky that our physicians have really
- 13:25Speaker 5: embraced this here at Saint Jude and generally do follow
- 13:27Speaker 5: those recommendations that are in that are in that chart.
- 13:31Speaker 5: So I think it's an incredibly important point because this
- 13:35Speaker 5: information will follow that patient for years. And there was
- 13:38Speaker 5: actually an incident in the children's hospital. This didn't happen
- 13:41Speaker 5: that long ago, but the patient had had a TPMT result.
- 13:44Speaker 6: It got put into the.
- 13:45Speaker 5: Electronic metal corecord just kind of as a PDF. I
- 13:49Speaker 5: think it took three or four clicks to even get
- 13:51Speaker 5: to that result. And because of this, a patient had
- 13:54Speaker 5: major toxicity to five hearings because they did not know
- 13:57Speaker 5: when they started the medication that this patient happened to
- 13:59Speaker 5: be a TP empty poor metabolizer.
- 14:02Speaker 6: So lessons learned.
- 14:03Speaker 5: And it was not Saint Jude, so lessons learned for
- 14:05Speaker 5: this pediatric hospital.
- 14:06Speaker 6: But and it did.
- 14:07Speaker 5: It did promote their you know, there's there's c suite
- 14:11Speaker 5: though to say, okay, maybe this is important, maybe we
- 14:13Speaker 5: should be you know, investing a bit more because it
- 14:15Speaker 5: it does take a lot of informatics support to get
- 14:19Speaker 5: this into your EHR. There are packages, I think, and
- 14:23Speaker 5: I don't want to mention any vendor specifically, but I
- 14:25Speaker 5: know about EPIC because we just went to EPIC that
- 14:28Speaker 5: maybe including more of this into their main package. So
- 14:31Speaker 5: maybe this in the future won't be so so time
- 14:34Speaker 5: demanding for people to get implemented. But once the patient
- 14:38Speaker 5: leaves Saint Jude forget it. Like I don't even know
- 14:41Speaker 5: what they do with these results. We do give them
- 14:42Speaker 5: to the patients. We do try to counsel the patients
- 14:45Speaker 5: but first off, their children. So I do think that
- 14:47Speaker 5: transition into care can impact that a lot too, because
- 14:50Speaker 5: maybe they got the test when they were ten, it's
- 14:52Speaker 5: another parent has to remind them about this test result.
- 14:55Speaker 5: We sent these letters out for a long time that
- 14:57Speaker 5: kind of summarize what the results were, but it was
- 15:00Speaker 5: put on the patient to take that information and give
- 15:03Speaker 5: it to the physician because of course, we have a
- 15:05Speaker 5: very fragment and healthcare system here in the United States,
- 15:07Speaker 5: and we all have different EHRs, and they don't speak
- 15:09Speaker 5: to each other, and because of this, I think that
- 15:12Speaker 5: there's a lot of information lost when you go from
- 15:14Speaker 5: one physician to another. In pharmacogenomics is probably one of
- 15:17Speaker 5: those best examples of where this or this can happen.
- 15:19Speaker 6: So I would love to hear ideas.
- 15:21Speaker 5: On how to Nobody has really come up with a
- 15:23Speaker 5: great solution on how to make these results more portable.
- 15:29Speaker 4: I think that perfecting piece.
- 15:30Speaker 7: Since we do try to get pharmacogenomics on everyone, one
- 15:33Speaker 7: of the things I tell them is, like, please bring
- 15:35Speaker 7: this PDF with you on your phone everywhere, and like
- 15:37Speaker 7: every doctor, pharmacist, or like healthcare professional that you encounter,
- 15:41Speaker 7: like give them the results because these are this is
- 15:43Speaker 7: like an important part of your footprint.
- 15:45Speaker 4: It's almost like your fingerprint.
- 15:46Speaker 7: So like the parents are like, okay, okay, we'll do it,
- 15:49Speaker 7: but we're currently building on our own like EMR right now,
- 15:52Speaker 7: where we're trying to make it more interoperable and we
- 15:55Speaker 7: do facts and send out the results to all the
- 15:57Speaker 7: positions that we interact with so they have it as
- 16:00Speaker 7: a frame of reference. I'm glad that a lot of
- 16:03Speaker 7: the physicians at Saint Jude are on board. But I
- 16:05Speaker 7: guess this is like an off the book question, just
- 16:08Speaker 7: like asking for us. I think some parents are hesitant
- 16:12Speaker 7: to do farmer unco genomics, So how do you.
- 16:14Speaker 4: Deal with that hesitation?
- 16:17Speaker 5: I think our exceptions, right, it's been around ninety seven
- 16:19Speaker 5: percent and great or greater, right, I mean, I think
- 16:22Speaker 5: you know, our patients come into our hospital, and I
- 16:24Speaker 5: think they do our approach with lots of protocols and
- 16:26Speaker 5: lots of things to consent to and a lot and
- 16:27Speaker 5: I bet it is a bit overwhelming.
- 16:29Speaker 6: We try not to overwhelm them too much, so it
- 16:31Speaker 6: is spaced out.
- 16:32Speaker 5: But I think so far most of our parents have
- 16:34Speaker 5: been pretty accepting this. Interestingly, when they get the results
- 16:38Speaker 5: now they actually ask how it impacts them. You know,
- 16:40Speaker 5: if they've got this high risk variant, the parents like,
- 16:43Speaker 5: oh do I have this variant, which is you know,
- 16:46Speaker 5: that means they are understanding what this means that they
- 16:49Speaker 5: you know, one of these variants definitely came from one
- 16:51Speaker 5: of the parents.
- 16:52Speaker 6: We're still trying to.
- 16:53Speaker 5: Deal with how to how to you know, how to
- 16:57Speaker 5: recommend you know, additional testing and for what genes you must,
- 16:59Speaker 5: but our parents have been pretty pretty accepting of it
- 17:03Speaker 5: because and then you know, again, we've got that great
- 17:05Speaker 5: example of TPMT nineteen fifteen and thiopearanes, and a lot
- 17:09Speaker 5: of our patients do get thiopearines while they're here.
- 17:11Speaker 6: So I think that that right there might be compelling enough.
- 17:16Speaker 3: Kelly, I want to go back to another thing that
- 17:17Speaker 3: you mentioned, and that is the idea of preemptive testing
- 17:20Speaker 3: versus reactive testing.
- 17:22Speaker 7: Right.
- 17:22Speaker 3: I think Saint Jude's has been a leader in pushing
- 17:25Speaker 3: for preemptive testing of pharmacogenomics. But I think if we
- 17:29Speaker 3: look outside, let's look at ambulatory care and other health systems,
- 17:34Speaker 3: I think often we're looking at this from a reactive standpoint.
- 17:39Speaker 3: So I'm going to want to give you the opportunity
- 17:42Speaker 3: to make your case, like, are we ready for prime
- 17:45Speaker 3: time and a lot of other places. Should we be
- 17:48Speaker 3: using preemptive pharmacogenomic testing more than we are? Or do
- 17:51Speaker 3: you think we're still learning and need to advance the
- 17:55Speaker 3: science a bit more.
- 17:57Speaker 6: I think it's a little bit of both.
- 17:58Speaker 5: Right, you have a panel of genes, and I would
- 18:00Speaker 5: say two or three of them on that panel. Yes,
- 18:02Speaker 5: I would absolutely say preemptively everybody should be tested for this.
- 18:05Speaker 6: But then there's some with maybe.
- 18:07Speaker 5: Lesser evidence, and maybe there's not a need to test
- 18:09Speaker 5: the entire population. But the testing price has come down
- 18:12Speaker 5: so much that ordering a single test versus and ordering
- 18:15Speaker 5: a panel test or there's barely a difference in the price.
- 18:18Speaker 5: So for me, it makes sense if you're going to
- 18:20Speaker 5: reactively order one gene, you might as well go ahead
- 18:23Speaker 5: and do the panel because now you've got other genes.
- 18:26Speaker 5: But of course you're still doing it reactively, and in
- 18:28Speaker 5: some cases it may take two weeks to get that
- 18:31Speaker 5: test result back, and depending on what the medication is,
- 18:34Speaker 5: that may be important that you know, you may start
- 18:37Speaker 5: a patient on an antidepressant and maybe you can't even
- 18:40Speaker 5: respond or see the patient for another month. But now
- 18:42Speaker 5: they've been on the wrong antidepressant for a full month.
- 18:45Speaker 5: And think about the DPID example. Right, You're starting this
- 18:48Speaker 5: chemotherapy on the patient and you don't get this test
- 18:50Speaker 5: result back for a while.
- 18:51Speaker 6: So having it preemptively makes a lot of sense.
- 18:54Speaker 5: I think that pharmacogenemics is the most useful at that
- 18:57Speaker 5: first initial dose versus you know, because you're going to
- 19:00Speaker 5: tie trade up to response or toxicity from a clinical standpoint,
- 19:03Speaker 5: but that can take months and sometimes years depending on
- 19:06Speaker 5: what the drug is to really get that patient therapeutic.
- 19:09Speaker 6: So preemptive to me makes you know, makes the most sense.
- 19:11Speaker 5: But I agree that maybe the data does it completely
- 19:14Speaker 5: support us doing it for every patient, But I do
- 19:17Speaker 5: think in about ten years will be there. I think
- 19:21Speaker 5: the more genes you test, the more likely you are
- 19:23Speaker 5: to be on a drug that one of these genes
- 19:25Speaker 5: tests one of these, yeah, one of these, one of
- 19:29Speaker 5: these deans may impact that drug therapy, So the more
- 19:31Speaker 5: likely that.
- 19:32Speaker 6: The test will be beneficial to the patient.
- 19:35Speaker 4: Let's just piggybacking off of Justin's question with preemptive testing,
- 19:38Speaker 4: how early is too early? Like, at what age should
- 19:40Speaker 4: we start this?
- 19:42Speaker 5: I mean at birth, it doesn't matter your genes aren't
- 19:44Speaker 5: really going to change over to the testing changes.
- 19:47Speaker 6: The testing doesn't free.
- 19:48Speaker 5: We are making a lot of improvements on the way
- 19:50Speaker 5: we test the variance that we test, but for the
- 19:54Speaker 5: most part, I think, really, you know, with that initial
- 19:58Speaker 5: you know, hospital visit for every infant, it would be
- 20:00Speaker 5: great if we were doing you know, more genomic testing
- 20:03Speaker 5: on those infants. So I don't think it matters when
- 20:05Speaker 5: you get tested, but certainly the earlier the better, I'd think.
- 20:10Speaker 4: Do we have to retest at any point or any age,
- 20:14Speaker 4: I don't.
- 20:14Speaker 5: You don't really need to, depends on what test you took, really, right,
- 20:17Speaker 5: So if you actually got a sequencing data back then,
- 20:19Speaker 5: they most likely collected most of the variations that you
- 20:22Speaker 5: may have in your genes, because there may you may
- 20:23Speaker 5: carry some variations that we don't know about yet.
- 20:27Speaker 6: We're still a very evolving field.
- 20:29Speaker 5: I think we update these se FIT guidelines on an
- 20:31Speaker 5: ongoing basis because of that, because we can't keep up
- 20:34Speaker 5: with the evidence for it, and so you know, as variants,
- 20:37Speaker 5: new variants are discovered, more populations that are getting tested,
- 20:40Speaker 5: we're seeing newer variants that may not be in certain
- 20:43Speaker 5: you know, the populations that we have tested, and so
- 20:46Speaker 5: I think that being retested really depends on what variations
- 20:50Speaker 5: were tested, what variants were tested that you know at
- 20:53Speaker 5: that time. I think we've done a pretty good job
- 20:55Speaker 5: recently of trying to standardize at least what variations are
- 20:59Speaker 5: what we call them allele, but what alleles are being
- 21:01Speaker 5: tested AMP So don't think they're the American they're blecular pathologists.
- 21:08Speaker 6: They've got now a list.
- 21:09Speaker 5: Of must test variants, and I think if you were
- 21:11Speaker 5: testing those must test variants, then your test is probably
- 21:15Speaker 5: pretty solid and you may not need to be retested.
- 21:17Speaker 5: But if the test missed quite a few of those variations,
- 21:21Speaker 5: then it may be worth your time, especially if you're
- 21:23Speaker 5: having side effects to drugs that could be impacted by
- 21:26Speaker 5: genetic variation, that maybe a retest might be worth it.
- 21:30Speaker 5: But I do think we're moving more into sequencing and
- 21:32Speaker 5: so maybe that fear will go away.
- 21:36Speaker 3: Well, Kelly, that brings me to another question. This is
- 21:38Speaker 3: a little bit broader, but I think more and more
- 21:42Speaker 3: we're seeing that even as pharmaco genomic panels grow, we
- 21:46Speaker 3: also have the technology of whole XOM and whole genome sequencing.
- 21:50Speaker 3: So for our listeners who maybe aren't in pharmacogenomics right now,
- 21:54Speaker 3: could you tell us a little bit of the difference
- 21:56Speaker 3: between our pharmacog genomic panels and then the differences with
- 22:01Speaker 3: who EXOM and whole genome sequencing, and then what information
- 22:04Speaker 3: we can gather from those.
- 22:06Speaker 5: So a panel just tests specific variations, you know, variations
- 22:09Speaker 5: that we know about already. Generally the variation the liles
- 22:14Speaker 5: that are the variants that are put onto these the
- 22:16Speaker 5: panels are ones that are you know, a higher frequency
- 22:20Speaker 5: in certain populations. They are known to be you know,
- 22:24Speaker 5: very damaging functionally, so we know that if patient has
- 22:28Speaker 5: this a very high they're at higher risk of some
- 22:31Speaker 5: type of drug toxicity.
- 22:33Speaker 6: But it's very targeted. So again they do range.
- 22:36Speaker 5: There's something as I said, there's a MP that does
- 22:38Speaker 5: some standardization, but you can they're not there's sometimes it's
- 22:41Speaker 5: like comparing apples to oranges. Some of these tests actually,
- 22:44Speaker 5: in my opinion, have genes that really shouldn't be tested
- 22:48Speaker 5: on them, and then the clinicians really left with thinking, well,
- 22:51Speaker 5: what do I do with this information? See picks Trying
- 22:54Speaker 5: to come overcome that a bit by including some of
- 22:56Speaker 5: these genes and our evidence reviews just so that we
- 22:59Speaker 5: can you know, really establish what genes should be on
- 23:02Speaker 5: these panels, but that is probably what you're going to
- 23:05Speaker 5: see most as panels.
- 23:06Speaker 1: Now.
- 23:07Speaker 5: XM sequencing means we're just sequencing the xms. There are
- 23:10Speaker 5: in tronic snips that that do DPYD has one that's
- 23:14Speaker 5: very important, so you do miss some variations if you
- 23:18Speaker 5: just do XM sequencing. And then full GENEM sequencing is
- 23:21Speaker 5: where we're just sequencing everything exons and entrons.
- 23:24Speaker 6: There there's a lot of computational work.
- 23:27Speaker 5: That goes along with with the sequencing work. So again
- 23:31Speaker 5: I think even though technically you would think each test
- 23:34Speaker 5: would pick up the same variations, I think sometimes there
- 23:37Speaker 5: still can be some downfalls to.
- 23:39Speaker 6: That as well.
- 23:39Speaker 5: But for the most part, they're picking up everything, and
- 23:41Speaker 5: when they pick up everything, then you're kind of left,
- 23:43Speaker 5: or what do we do? What if c pick doesn't
- 23:45Speaker 5: have this variation on their on their you know, on
- 23:48Speaker 5: their charts, or they're sorry their tables, what do you
- 23:50Speaker 5: do with it? It becomes you know, so sometimes too
- 23:53Speaker 5: much information can be bad as well.
- 23:57Speaker 3: Yeah, that's true, especially without a systematic way of necessarily
- 24:00Speaker 3: sorting through it. And it requires a major amount of
- 24:03Speaker 3: data to really understand each of these variants. Yes, we
- 24:07Speaker 3: can learn things from case reports and we can gather
- 24:11Speaker 3: valuable data, but to really analyze the effect, we've got
- 24:15Speaker 3: to have just massive amounts of data for sure.
- 24:18Speaker 2: Yeah.
- 24:21Speaker 3: So one of the other things that we know is
- 24:24Speaker 3: when we're looking at the human genome, there is a
- 24:26Speaker 3: lot of variation. Yes, our DNA is very similar, but
- 24:31Speaker 3: it's the variations that make us different from one another.
- 24:34Speaker 3: And we know that even in particular groups that may
- 24:38Speaker 3: be geographically located in other parts of the world, we
- 24:41Speaker 3: may see variants at higher levels, right based on heredity
- 24:47Speaker 3: and other things. So could you give us some examples
- 24:49Speaker 3: of maybe a specific group that might be at higher
- 24:53Speaker 3: risk for a particular adverse reaction because of their genome.
- 24:57Speaker 5: I think probably the best example of it us as
- 25:00Speaker 5: our HLAB. It's HLB star fifteen oh two. This has
- 25:04Speaker 5: been associated with Stevens Johnson a syndrome and patients taking
- 25:07Speaker 5: carbbook carbon mazon PM.
- 25:09Speaker 6: This one.
- 25:10Speaker 5: The frequency varies a lot depending on the population. So
- 25:14Speaker 5: the frequency is about six point nine percent in East
- 25:17Speaker 5: Asian population, but not all subpopulations of East Asia, and
- 25:22Speaker 5: this is really low in African and Japanese populations and
- 25:25Speaker 5: Caucasian populations so low in a lot of others, however,
- 25:29Speaker 5: and I want to point this out that you know,
- 25:31Speaker 5: if a patient has this variant, no matter what their
- 25:34Speaker 5: genetic ancestry is, they're still at rest for the carbon
- 25:37Speaker 5: mazing pine associated you know, Stevens Johnson. It's just that
- 25:40Speaker 5: we see higher rates of the side effect in these
- 25:44Speaker 5: other populations because they have a higher frequency of this
- 25:47Speaker 5: particular variant. Because there's the I think the FDA label
- 25:51Speaker 5: still only recommends testing in certain populations that a lot
- 25:55Speaker 5: of people don't even know really where they're from, and
- 25:57Speaker 5: so that can be tricky. And there's been case report
- 26:00Speaker 5: to patients that are that are not Asian that have
- 26:02Speaker 5: an HLA B star fifteen O two. So you know,
- 26:06Speaker 5: I think when we talk about populations, in my opinion,
- 26:09Speaker 5: if you have the variant, you should act on it
- 26:11Speaker 5: because it really should affect, especially for something like ahlab
- 26:14Speaker 5: or a drug metabolizing ins on it. It shouldn't really
- 26:16Speaker 5: matter what you're with, your your genetic ancestry is to
- 26:20Speaker 5: act on that.
- 26:23Speaker 7: I guess, going off the line of other populations, are
- 26:26Speaker 7: there any common comorbidities that are associated with higher risks?
- 26:31Speaker 5: Most pharmacogenomic variations don't really have diseases that are associated
- 26:36Speaker 5: with them. I think that one of the good examples,
- 26:38Speaker 5: I guess is u T one A one. It is
- 26:42Speaker 5: involved with I guess, conjugating billy rubin and so that
- 26:45Speaker 5: you can eliminate it so page people. And there's also
- 26:48Speaker 5: some pharmacogenomic issues because it does it does metabolize drugs
- 26:52Speaker 5: as well. But patients that are for metabolizers for u
- 26:55Speaker 5: g T one a one can have higher, you know,
- 26:59Speaker 5: levels of unconjugated billy rubens. Some patients may know maybe
- 27:03Speaker 5: their skins a little yellow, eyes can be a little yellow.
- 27:06Speaker 6: But I would think in.
- 27:07Speaker 5: Most cases it's pretty subclinical and doesn't really cause any
- 27:11Speaker 5: major effects.
- 27:12Speaker 6: For the patient. So I don't know.
- 27:14Speaker 5: Maybe it's I think it's called a syndrome, not really
- 27:15Speaker 5: a disease, but it's yeah. I think u G T
- 27:19Speaker 5: one a one might be the best example. In the
- 27:21Speaker 5: CEPIT guideline, we do have an.
- 27:24Speaker 6: Entire section on what we call incidental findings.
- 27:27Speaker 5: So we may have ordered the gene because we were
- 27:31Speaker 5: going to prescribe a particular drug, but does it have
- 27:34Speaker 5: other effects on disease? And I don't think for any
- 27:37Speaker 5: other of our guidelines except for maybe G six p D,
- 27:39Speaker 5: which is an obvious one.
- 27:42Speaker 6: We have much in there about diseases.
- 27:44Speaker 3: For that, Kelly, I wanted to ask you a question
- 27:51Speaker 3: to kind of dispel a myth that I've heard, maybe
- 27:53Speaker 3: an assumption that pharmacists and other clinicians make. So we
- 27:57Speaker 3: know that throughout the developments of children and a lot
- 28:00Speaker 3: of our enzyme systems are ramping up in terms of expression, right,
- 28:05Speaker 3: So we often will think about cytochrome P four fifty enzymes,
- 28:09Speaker 3: which many of them may not be fully expressed or
- 28:12Speaker 3: reaching adult values until two years of age, some of
- 28:15Speaker 3: them maybe later. Some the activity may be higher in
- 28:18Speaker 3: kids than it is later in adulthood. So here's my question.
- 28:24Speaker 3: Considering that expression might change, does that mean that we
- 28:27Speaker 3: need to retest or do we have all the information
- 28:30Speaker 3: about genotype that we need from the first testing of
- 28:35Speaker 3: pharmacogenomic data for a child.
- 28:37Speaker 6: Yeah.
- 28:37Speaker 5: No, the change of expression may affect their phenotype, but
- 28:40Speaker 5: it's not going to really affect their genotype.
- 28:42Speaker 6: So yeah, I think that's probably the best way to
- 28:46Speaker 6: answer that question.
- 28:47Speaker 3: Okay, great, thank you, Kelly.
- 28:50Speaker 7: Sorry to go off the book with this, but a
- 28:52Speaker 7: lot of parents will ask me about like getting like
- 28:54Speaker 7: a twenty three and meters like pharmacogenomics test.
- 28:57Speaker 4: Are those like? How valid are those?
- 28:59Speaker 7: And should we retest if they did do something like
- 29:02Speaker 7: that for their child?
- 29:04Speaker 5: Oh, twenty three am is an interesting example. They're you know,
- 29:08Speaker 5: looking at the last test that they had. They're not testing.
- 29:11Speaker 5: First off, they don't test at two D six because
- 29:13Speaker 5: the two D six has coffee numbers, and to me,
- 29:15Speaker 5: that's one of the most important pharmaca genes. But I mean,
- 29:19Speaker 5: you can get your raw results and we can tell
- 29:21Speaker 5: you what the variants are there, but it still doesn't
- 29:23Speaker 5: tell you the coffee number, which is important for the
- 29:25Speaker 5: ultra rapid metabolizer phenotype.
- 29:28Speaker 7: Black Friday coming up. I know a lot of parents.
- 29:31Speaker 7: I honestly am a funny person. I gave everyone like
- 29:34Speaker 7: an ancestry test one year for Christmas because they're on
- 29:37Speaker 7: sale like this day maybe last year, just so everyone
- 29:40Speaker 7: would know like their genealogy. So if I decided to
- 29:43Speaker 7: batch by everyone a twenty three and me, should they
- 29:46Speaker 7: get a retest?
- 29:47Speaker 6: All right? Sorry? Sorry about that.
- 29:48Speaker 5: Yes I would because it's twenty three and meters and
- 29:51Speaker 5: I don't I feel like they're they're variant, they're they're
- 29:54Speaker 5: missing a gene and then the variants that they have
- 29:58Speaker 5: there that I don't even think they meet that. I'm
- 30:00Speaker 5: maybe saying something wrong here, so I apologize if I am,
- 30:02Speaker 5: but I don't think they meet that a MP recommendation
- 30:05Speaker 5: for the variation. So I would look at those reports
- 30:08Speaker 5: see what variants they tested for to make sure that
- 30:11Speaker 5: it was more comprehensive.
- 30:14Speaker 6: Than less.
- 30:14Speaker 5: Again, though, I think you can still get your raw data,
- 30:16Speaker 5: so you can should You should be able to pull
- 30:17Speaker 5: a lot more information from that if you know what
- 30:19Speaker 5: you're doing.
- 30:20Speaker 6: But I do enjoy the ancestry part of that.
- 30:23Speaker 5: That was really cool because I've done twenty three in
- 30:25Speaker 5: me and I learned a lot about myself from that,
- 30:28Speaker 5: so it was it was still I thought worth doing.
- 30:32Speaker 5: I think it's an add on maybe or it's a
- 30:34Speaker 5: separate package for twenty three and me, but it's still interesting.
- 30:38Speaker 6: So it's a fun gift. I guess it's a really.
- 30:41Speaker 4: Fun gift to Mike. Well, you think you know about yourself,
- 30:43Speaker 4: but I'm going to I'll help you find out a
- 30:45Speaker 4: little bit more.
- 30:49Speaker 3: Mary, you're helping me to do my Christmas shopping right now,
- 30:51Speaker 3: So thanks for the great idea.
- 30:52Speaker 7: Here.
- 30:54Speaker 3: So another thing Kelly, that I was hoping to get
- 30:57Speaker 3: some of your guidance on. We might have a lot
- 31:00Speaker 3: of our listeners that are considering talking with their clinics
- 31:03Speaker 3: or the different practice areas that they're in about considering
- 31:08Speaker 3: more pharmacogenomic testing. Now, we know that there are a
- 31:10Speaker 3: lot of different panel panels on the market, different companies
- 31:14Speaker 3: that are in that space. So what would be some
- 31:17Speaker 3: practical guidance you would give about how to evaluate the
- 31:23Speaker 3: different platforms or tests that are out there if you
- 31:26Speaker 3: were to try to select one for your own clinic
- 31:28Speaker 3: or practice.
- 31:30Speaker 1: I mean, I might be a little biased here, but
- 31:32Speaker 1: I would go to the Seedpick guidelines and make sure
- 31:35Speaker 1: that the test had on the genes that Cepick has
- 31:39Speaker 1: guidelines for.
- 31:41Speaker 5: I would make sure that the variants meet that AMP requirement.
- 31:45Speaker 5: They got tier one and tier two, and I would
- 31:47Speaker 5: shoot for tier two if you can. And I think
- 31:49Speaker 5: a lot of the companies are moving in that they're
- 31:51Speaker 5: doing both tier one and tier two now at least
- 31:53Speaker 5: I've seen some changes there.
- 31:55Speaker 6: I would be really careful though about using the report.
- 32:00Speaker 5: You know, make sure you've got someone that can interpret
- 32:04Speaker 5: Some of these have to be reinterpreted. If you're going
- 32:06Speaker 5: to use the c PICK guideline, you've got to be
- 32:08Speaker 5: using our genotype to phenotype translations.
- 32:11Speaker 6: And some of these companies.
- 32:12Speaker 5: Don't do it the same way that SEPICK does, even
- 32:15Speaker 5: though they still reference our guidelines and their recommendations, but
- 32:19Speaker 5: it's not the same. So I highly recommend not to
- 32:22Speaker 5: do it alone and have someone order it that can
- 32:26Speaker 5: help you interpret it, because it's not It's not as
- 32:28Speaker 5: straightforward as it sounds.
- 32:30Speaker 6: So whatever test you order, helly long lines of interpreting.
- 32:34Speaker 7: We are interpreting our tests ourselves, and we're using SEPICK,
- 32:39Speaker 7: and we're using like the pharmacal genomics sections of like
- 32:42Speaker 7: a lot of drug databases. I've also used pharm gh
- 32:46Speaker 7: GHB or GKB before, but it's just like a lot
- 32:50Speaker 7: to process. I guess as just someone that practiced in
- 32:54Speaker 7: pediatrics and doesn't really have a pharmacogenomics background besides my one.
- 32:59Speaker 4: Elective pharmacy school.
- 33:01Speaker 7: What are your suggestions for additional education or like certification
- 33:05Speaker 7: programs that pharmacists can look into.
- 33:07Speaker 6: Yeah, there are several across the country. I think Florida
- 33:10Speaker 6: has one.
- 33:11Speaker 5: Oh man, they got they come and go, So I
- 33:13Speaker 5: can't remember all of the programs. ACCP used to have
- 33:16Speaker 5: one AA. Shp's got a really good program. I just
- 33:19Speaker 5: hired a new pharmacist to help with CPIC and I
- 33:23Speaker 5: asked her to take the AA just to get her
- 33:24Speaker 5: some good foundational knowledge, and she felt like it was
- 33:27Speaker 5: a great program. I'm not putting a plug in for
- 33:29Speaker 5: any of these programs because that not personally taking them
- 33:31Speaker 5: quick clear, because I think I wrote a lot of them.
- 33:33Speaker 5: But I do, but I do think, but I do
- 33:37Speaker 5: think you know, just kind of wing what the options are,
- 33:39Speaker 5: but doing that getting that foundational knowledge, especially if you
- 33:42Speaker 5: didn't get it in pharmacy school, I think is important
- 33:44Speaker 5: for every pharmacist in those programs. They exist, They are
- 33:49Speaker 5: certainly out there. You just have to you have to
- 33:51Speaker 5: find them.
- 33:53Speaker 3: Yeah, I could not agree more. I've I've benefited greatly
- 33:56Speaker 3: from completing one of those programs that you've mentioned, And
- 34:00Speaker 3: not only did it give me skills and knowing how
- 34:03Speaker 3: to properly interpret and not just trusting those interpretive reports
- 34:07Speaker 3: that come from many of the companies, but it also
- 34:10Speaker 3: simply opened my eyes to be thinking differently and more
- 34:13Speaker 3: holistically about the patients I serve. I found myself asking
- 34:16Speaker 3: different questions and caring about ancestry because that may impact
- 34:20Speaker 3: depending on the drugs we're considering in mental health or
- 34:23Speaker 3: somewhere epilepsy or somewhere else, what we select. And so
- 34:28Speaker 3: I would just put a plug in that all pharmacists,
- 34:31Speaker 3: this should be a basic competency that we really want
- 34:34Speaker 3: to have. It's another tool in our tool belt to
- 34:36Speaker 3: help us be great clinicians, and it's also one of
- 34:40Speaker 3: those things that I think pharmacists should own as the experts.
- 34:44Speaker 3: We have a lot of people to have a little
- 34:46Speaker 3: bit of knowledge, but sometimes, like a lot of things
- 34:49Speaker 3: in medicine, a little bit of knowledge can be just
- 34:51Speaker 3: enough to hurt someone, right, and so you want to
- 34:53Speaker 3: make sure you're competent with it and you can handle
- 34:55Speaker 3: that really well. So with that, Kelly, I wanted to
- 34:59Speaker 3: transition to time talking a little bit about some of
- 35:01Speaker 3: the resources that are available through c PICK and also
- 35:04Speaker 3: maybe farm GKB as well, which I use all the time.
- 35:09Speaker 3: And I particularly would love to hear a little bit
- 35:12Speaker 3: more about the Gene Selection Interface, the GSI, which I
- 35:15Speaker 3: absolutely love as well. So I just want to, I guess,
- 35:19Speaker 3: give you a chance to plug some of those resources
- 35:22Speaker 3: and tell us more about where pharmacists can go to
- 35:24Speaker 3: learn about how to implement pharmacogenemics.
- 35:27Speaker 5: Yeah, farm GKV is an incredible resource and I agree.
- 35:31Speaker 6: I love the DSi you can put in.
- 35:34Speaker 5: You can put in your entire report, so from the
- 35:36Speaker 5: diplot and usually you put in you can put in
- 35:38Speaker 5: your diplot type, you can put in your phenotype and
- 35:40Speaker 5: it will print out a report.
- 35:41Speaker 6: It will show you what CPICK says.
- 35:43Speaker 5: There's another group called the Dutch Pharmacogenemic Working Group that
- 35:46Speaker 5: also has clinical practice guidelines for pharmacogenemics.
- 35:49Speaker 6: It has their recommendations.
- 35:50Speaker 5: There which are generally pretty similar to a C PICK
- 35:54Speaker 5: and then there's the FDA labeling. They also compare it
- 35:56Speaker 5: to so you can see it to really across what
- 35:58Speaker 5: three resources say and that one easy report versus having
- 36:01Speaker 5: to go and pool every single seedpit guideline and look
- 36:05Speaker 5: at these.
- 36:07Speaker 6: Farm GKB to me is also really great.
- 36:09Speaker 5: So if you've ever gone to an FDA label and
- 36:11Speaker 5: tried to find the pharma coachemic information within it, it
- 36:14Speaker 5: is it's all over the place. They also they also
- 36:17Speaker 5: annotate those like labels, and not just US.
- 36:19Speaker 6: They do European.
- 36:20Speaker 5: They've got I think Japan and a few weathers, so
- 36:22Speaker 5: it's it's also to me a great resource where you
- 36:25Speaker 5: can quickly find you know what, at least what the
- 36:27Speaker 5: drug label says, even though I think you should practice
- 36:29Speaker 5: way outside the drug label.
- 36:31Speaker 6: A lot of these are outdated. They haven't really included
- 36:33Speaker 6: a lot of pharmacogenemic information yet. It may be coming.
- 36:36Speaker 5: But farm GKB you can also go and there's clinical
- 36:39Speaker 5: annotations in there. Where let's say there's no Sepitt guideline,
- 36:42Speaker 5: no Dutch guideline, and the FDA label is very vague
- 36:44Speaker 5: about what maybe it mentions it, but it's pretty vague
- 36:46Speaker 5: and you're like, I don't know what to do. They
- 36:48Speaker 5: also have these clinical annotations, so at least you instead
- 36:51Speaker 5: of having to go to pub med and do a
- 36:53Speaker 5: pub Med search yourself, you can at least go there
- 36:55Speaker 5: and see what information they have already pulled. It's definitely
- 36:59Speaker 5: a few steps ahead for that busy physician that may
- 37:01Speaker 5: not have time to really dig deep into into the literature.
- 37:05Speaker 5: We're working sepicks, working as fast as we can to
- 37:07Speaker 5: get through our lists, but these guidelines take one to
- 37:09Speaker 5: two years to do, so hopefully that won't be too
- 37:12Speaker 5: much of.
- 37:12Speaker 6: A barrier much longer, but I think it is.
- 37:14Speaker 5: But yeah, the people Terry Klein, who's also the co
- 37:17Speaker 5: PI of c Pick, is also the PI of farm GKB,
- 37:22Speaker 5: and they've done a phenomenal job.
- 37:24Speaker 6: But I do want to pe a plug in here.
- 37:25Speaker 6: We're going to be combining our resources soon.
- 37:27Speaker 5: I don't know if this is if you guys know yet,
- 37:29Speaker 5: but Cepick, we have the c Pick website, we have
- 37:32Speaker 5: Farm GKB. You're you're going to start seeing what's called
- 37:35Speaker 5: Clenn pg X if you go to the farm GK website,
- 37:38Speaker 5: it's called automatically going to push you into Glenn pg
- 37:41Speaker 5: X that have a lot of the same features as
- 37:43Speaker 5: as farm GKB does, but with a lot other things
- 37:46Speaker 5: where it's really just combining our two resources into one database.
- 37:50Speaker 5: We are both funded independently through the NIH and that's
- 37:52Speaker 5: going to stop as well. So we thought combining as
- 37:55Speaker 5: much as we could made a lot of sense. And
- 37:57Speaker 5: so you'll be hearing Actually this year, stead of having
- 37:59Speaker 5: this Pick meeting, we had the Clein PGX meeting. So
- 38:02Speaker 5: some changes coming to that, but those features will all
- 38:05Speaker 5: still be there, and Terry will be so excited that
- 38:07Speaker 5: you enjoy those features because I know they worked hard
- 38:10Speaker 5: on those.
- 38:11Speaker 3: I can't imagine the time that they put into developing
- 38:14Speaker 3: the gene selection interface. I will put another plug in
- 38:17Speaker 3: for my fellow pediatric clinicians here. When you go to
- 38:22Speaker 3: farm GKB, and I'm guessing this will continue to be
- 38:24Speaker 3: there with any other resources, you have the option to
- 38:28Speaker 3: select Ped's focus when you're looking at your data. So
- 38:32Speaker 3: I would encourage you if you are in pediatrics, when
- 38:35Speaker 3: you go to FARMGKB dot org, go ahead and click
- 38:38Speaker 3: that peds Focus. What it does is it highlights and
- 38:41Speaker 3: really puts front and center the pediatric specific data that
- 38:47Speaker 3: is informing the SEPICK recommendations and of course all the
- 38:51Speaker 3: resources that are there and firm GKB. So click the
- 38:54Speaker 3: peds Focus button. It is super helpful.
- 38:57Speaker 6: Great forgot about that justin. Thank you, thank you, thank
- 39:00Speaker 6: you for that blood there.
- 39:02Speaker 3: Oh yeah, absolutely, justin.
- 39:04Speaker 7: I know that you mentioned that you are a part
- 39:06Speaker 7: of sea PICK that's now going to be called CPGX.
- 39:09Speaker 7: If a pharmacist wants to join, is there an opportunity
- 39:13Speaker 7: to join?
- 39:13Speaker 4: How do how does that usually work?
- 39:16Speaker 5: Well?
- 39:17Speaker 3: I could, I could tell my story, but I think
- 39:19Speaker 3: Kelly's probably more qualified to answer that.
- 39:22Speaker 5: Yeah, So Seapick's going to remain Seapicks, even though we're
- 39:25Speaker 5: going to be combined in the clint PGX, so we
- 39:27Speaker 5: still will have sea Pick members. Clint PGX will have
- 39:29Speaker 5: more will we called users, and I think we're still
- 39:32Speaker 5: deciding how that may look. But Sea Pick as long
- 39:35Speaker 5: as you you can join sea Pick, it is free
- 39:37Speaker 5: to join.
- 39:38Speaker 6: You can go to our website.
- 39:39Speaker 5: I think there's a little thing at the tab at
- 39:42Speaker 5: the top it says members you click on that. What
- 39:45Speaker 5: we're looking for, though, is are people that are that
- 39:49Speaker 5: can contribute mostly to what we're doing.
- 39:51Speaker 6: Right, So think about that when before we have.
- 39:53Speaker 5: People that apply that are in the sales for pharmacoe gynomics,
- 39:56Speaker 5: and we're like, oh no, no, no, we want we
- 39:57Speaker 5: want our scientists, our pharmacists, our physicians that can really help,
- 40:02Speaker 5: you know, promote and disseminate the sea Pick guidelines. Because
- 40:05Speaker 5: those monthly calls, we have over two hundred and fifty
- 40:09Speaker 5: people calling into those calls monthly, which I've found to
- 40:11Speaker 5: be a big win for us because we're able to
- 40:14Speaker 5: update people on every change that we've made. We have
- 40:16Speaker 5: great speakers that come every month. So I encourage you
- 40:19Speaker 5: if you've got an interest in pharmacogenomics. You do have
- 40:21Speaker 5: to send your CV and signed MoU and EMOU just says, Hey,
- 40:25Speaker 5: I'm a pharmacade I'm going to be using pharmacogenemics. I
- 40:28Speaker 5: want to learn more about it and I will participate.
- 40:30Speaker 5: That's pretty much what the MU says.
- 40:33Speaker 6: And then we asked us for a self nomination letter,
- 40:35Speaker 6: just explaining.
- 40:35Speaker 5: To us why you want to be a ce PICK member,
- 40:38Speaker 5: and it really doesn't take long. Just just tell us,
- 40:40Speaker 5: tell us what you what your goal is to be
- 40:43Speaker 5: a c PICK member.
- 40:46Speaker 4: Pre cool.
- 40:46Speaker 7: So for all our pharmacists out there, I think that's
- 40:49Speaker 7: a great opportunity because it's such a growing field and
- 40:52Speaker 7: like I love just learning every day.
- 40:54Speaker 4: So I feel like I applying that was a selfish
- 40:58Speaker 4: question for myself.
- 41:00Speaker 7: So we're running down to the last few minutes of
- 41:02Speaker 7: our podcast, Kelly, do you have any last remarks or
- 41:06Speaker 7: any advice to pharmacists, physicians, parents.
- 41:10Speaker 5: I just reached out to try to get just find
- 41:13Speaker 5: some knowledge, understand what you're doing, you know, don't Like
- 41:16Speaker 5: I loved what was said earlier that a little bit
- 41:19Speaker 5: of knowledge can be harmful, and I completely agree with that.
- 41:21Speaker 5: I've seen that in practice where someone doesn't truly understand
- 41:24Speaker 5: how to use the SEPIT guideline. And I don't know
- 41:26Speaker 5: if they you know, directly cause harm, but they could have,
- 41:30Speaker 5: you know, maybe changing a drug that didn't need to
- 41:32Speaker 5: be changed, you know, things like that. So I highly
- 41:34Speaker 5: recommend trying to get a little bit more information about pharmacogenomics,
- 41:37Speaker 5: even it's just baseline knowledge and I forgot that I
- 41:41Speaker 5: needed to plug or We do have a residency program
- 41:43Speaker 5: here for pharmacogenomics, so if you really want, and there's
- 41:46Speaker 5: other programs out there.
- 41:47Speaker 6: But I think ours is the best.
- 41:48Speaker 5: Clearly think there's my disagree but you really get to
- 41:53Speaker 5: work with the people in the world that are really
- 41:55Speaker 5: started and really you know, serve as the model for
- 41:58Speaker 5: implementation of pharmacogenomics, and I think it's a great opportunity.
- 42:01Speaker 6: It's at PGI two.
- 42:03Speaker 5: We want our PGR ones to come in with some
- 42:05Speaker 5: clinical skills because you really are just layering on to
- 42:08Speaker 5: what you already know and you're doing pharmacogenemics, but you
- 42:10Speaker 5: do learn how to implement it well.
- 42:13Speaker 3: Kelly, thank you so much for joining us and confident
- 42:16Speaker 3: that our listeners have learned a ton and I'm as
- 42:19Speaker 3: excited as ever about pharmacogenomics and how we can use
- 42:22Speaker 3: it to better the care of the kids that come
- 42:23Speaker 3: our way, regardless of whether it's at Saint Jude or
- 42:26Speaker 3: at Perfecting Pedes, or whether it's in another clinic or
- 42:29Speaker 3: hospital around the US. So thank you so much for
- 42:31Speaker 3: lenning your expertise. Keep up the great work. Thanks for
- 42:34Speaker 3: your leadership along with your partners at CPICK. We look
- 42:38Speaker 3: forward to more to come.
- 42:39Speaker 6: Thank you, this was great. I appreciate the invitation.
- 42:41Speaker 2: That's all for today's episode. Thanks for listening, and remember
- 42:45Speaker 2: to subscribe on Apple Podcasts and leave us a review.